MeiraGTx reports FY2023 net loss of $84M, down 35% YoY; Janssen deal yields $50M milestone

MeiraGTx Holdings plc

Net loss $84.0M ($1.49/share) vs $129.6M ($2.87) in 2022; license revenue $14.0M.
Janssen asset purchase for bota-vec (XLRP) up to $415M; $65M upfront + $50M milestone in Feb 2024.
Sanofi invested $30M at $7.50/share; ROFN for riboswitch in CNS, I&I, metabolic disease.
FDA aligns Phase 2 AQUAx2 for xerostomia as pivotal; AAV-AIPL1 shows meaningful responses in 8 LCA4 children.
Cash $129.6M at Dec 31, 2023; expects funding into Q1 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

MeiraGTx Holdings plc reported financial results for the fourth quarter and full-year ended December 31, 2023.

Period: the fourth quarter and full-year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 14, 2024, MeiraGTx Holdings plc (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

MeiraGTx Holdings plc filing history →

Source: SEC EDGAR

accession 0001558370-24-003175

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.